Scholarlink

<p>A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月18日

查看全文
  • Sebastian Galeano,
  • Carmem Bonfim,
  • Amado Karduss,
  • Gregorio Jaimovich,
  • Andrés Gómez-De León,
  • Gustavo Bettarello,
  • Anderson Simione,
  • Cinthya Correa,
  • Helen Baldomero,
  • Daniel Neumann,
  • Ana Lisa Basquiera,
  • Mariano Berro,
  • Guillermina Remaggi,
  • Ariel Amaru,
  • Fernando Barroso,
  • Adriana Seber,
  • Francisco Barriga,
  • Julia Palma,
  • Bárbara Puga,
  • Matías Sánchez,
  • Juan Manuel Herrera,
  • Calixto Hernández,
  • David Gómez-Almaguer,
  • Félix Gaytán Morales,
  • Guillermo J. Ruiz-Argüelles,
  • Ninotzka Mendoza,
  • María Liz Benítez,
  • Alfredo Wong,
  • Carolina Pagés,
  • Marcos Hernández,
  • Dietger Niederwieser,
  • Damiano Rondelli,
  • Cristóbal Frutos

摘要

A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.